As of February 26, 2015

Wednesday, March 25

TIME	SESSION #	SESSION	COURSE DIRECTOR(S)	NOTES	CREDITS
7:30am – 5:15pm	220	Kidney Transplantation 2015	Fuad Shihab, MD, FNKF	• 101	7.75
7:00am – 5:00pm	221	Integrated Hemodialysis/Peritoneal Dialysis	Joanne Bargman, MD, FRCPC	• 101	8.0
7:30am – 4:30pm	222	CKD Management Along the Continuum: From Predialysis to Policy Supported by an educational grant from AstraZeneca	Charmaine Lok, MD, MSc, FNKF Christopher Chan, MD, FRCPC	• 101	7.25
8:00am – 6:00pm	223	Glomerular Diseases: Updates on Pathogenesis and Treatment	Fernando Fervenza, MD, PhD FNKF Michael Choi, MD, FNKF	• 101	7.5
6:30pm — 8:00pm	100	Career Choices in Nephrology/Fellows Reception Supported in part by Alexion Pharmaceuticals, Inc. Faculty: Jeffrey Berns, MD, FNKF; Steven Brunelli, MD; Michael Choi, MD, FNKF; Charmaine Lok, MD, MSc, FNKF; Claudia Lora, MD; Dan Negoianu, MD; Beth Piraino, MD, FNKF; Milagros Samaniego, MD, FACP, FASN; Francesca Tentori, MD; Miguel Vazquez, MD; Daniel Weiner, MD, MS, FNKF; John Wigneswaran MD, Wolfgang Winkelmayer, MD, ScD, MPH, FASN	Sylvia E. Rosas, MD, MSCE, FNKF	Ĭ	

Thursday, March 26

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am	800	Breakfast Symposium: Hyperkalemia and Emerging Treatments in Chronic Kidney Disease Supported by an educational grant from ZS Pharma	Chair: Csaba Kovesdy, MD	101	1.5
		Clinical Settings of Hyperkalemia	Csaba Kovesdy, MD		
		Limitations in the Acute and Chronic Treatment of Hyperkalemia	Jerry Yee, MD, FNKF	-	
		Emerging Treatment Options for Hyperkalemia	Wolfgang Winkelmayer, MD, ScD, MPH, FASN	-	
6:00am – 7:45am 801	801	Breakfast Symposium: Getting Ahead of Metabolic and Mineral Disturbances in the Management of CKD-MBD: A Focus on Management Strategies Supported by an educational grant from Sanofi Renal	Chair: Ellie Kelepouris, MD, FAHA	101	1.5
		Pathophysiology of CKD-MBD and Cardiovascular Consequences	Rajnish Mehrotra, MD, FNKF	-	
		Assessment of Dietary Interventions to Mitigate Risk	Kathleen Hill Gallant, PhD, RD, CD	_	
		Medical Management of Altered Calcium and Phosphorus in the Patient with CKD-MBD	Ellie Kelepouris, MD, FAHA		
8:00am – 9:30am	260	Dialysis Access: A Fragile Lifeline	Chairs: Charmaine Lok, MD, MSc, FNKF, and Michael Allon, MD		1.5
		Tale of Neglected Aneurysm	Tushar Vachharajani, MD, FASN, FACP	_	
		Pros and Cons of Forearm AVG Before Upper Arm AVF	Michael Allon, MD	_	
		Pros and Cons of Buttonhole	Charmaine Lok, MD, MSc, FNKF		
8:00am – 9:30am	261	Management of Patients with Glomerular Disease	Chairs: Debbie Gipson, MD, FNKF, and Fernando Fervenza, MD, PhD, FNKF		1.5
		Optimizing Outcomes in IgA Nephropathy	Michael Choi, MD, FNKF	_	
		Integrating Progress in Membranous Nephropathy into Clinical Practice	David Salant, MD	_	
		Getting it Right in ANCA Vasculitis: The Right Test and the Right Treatment for the Right Patient	Patrick Nachman, MD	_	

As of February 26, 2015

3:00am – 9:30am	262	Long-Term Outcomes in Kidney Transplantation	Chairs: Fuad Shihab, MD, FNKF, and Ajay Israni, MD		1.5
		Pathology and Causes of Long-Term Graft Loss	Arjang Djamali, MD		
		Recurrent Disease in the Renal Allograft	David Cohen, MD		
		Dealing with Threats to Patient Survival	Donald Hricik, MD		
9:30am – 10:00am		Break	•		
10:00am – 11:30am	263	Controversy: Age-Stratified Thresholds of GFR for Defining CKD	Chair: Kamyar Kalantar-Zadeh, MD, PhD, MPH, FNKF		1.5
		Pro: A Proposal to Modify the 2012 KDIGO Guidelines	Richard Glassock, MD		
		Con: The 2012 KDIGO Guidelines Got It Right	Andrew Levey, MD		
10:00am – 11:30am	264	Preparing for the New Kidney Allocation System	Chairs: Fuad Shihab, MD, FNKF, and Milagros Samaniego, MD, FACP, FASN		1.5
		Evolution and Understanding of the New Kidney Allocation System	Ajay Israni, MD		
		Ethics of Organ Allocation and Overcoming Racial Disparities in Organ Allocation	Sandra Amaral, MD		
		How Would the New Kidney Allocation System Affect the Patient on the Waiting List (Case Presentation)	David Cohen, MD		
10:00am – 11:30am	288	Pursuit of High Value Care for Persons with Kidney Diseases	Shari Ling, MD		1.5
11:30am – 12:00pm		Break			
·	802	Lunch Symposium: What Clinicians Need to Know About How Biosimilars Will Change the Treatment of Chronic Kidney Disease Supported by an educational grant from Hospira	Chair: Jay Wish, MD	101	1.5
		Biosimilars Regulation and Development in the United States	Edward Li, PharmD		
		Treating Anemia with Biosimilars: Exploring Risks and Benefits	Francesco Locatelli, MD		
		Operationalizing the Use of Biosimilar ESAs in the U.S.	Jay Wish, MD		
12:00pm – 2:00pm	230	Lunch Workshop: Hypertension in the CKD Population – Case-Based Presentation	Chairs: Debbie Cohen, MD, and Raymond Townsend, MD, FAHA	• 101	2.0
		Diagnosis and Management of Hyperaldosteronism	Raymond Townsend, MD, FAHA		
		Diagnosis and Management of Hypertension in Pheochromocyoma	Debbie Cohen, MD		
		Management of the Patient with Supine Hypertension and Orthostatic Hypotension	Raymond Townsend, MD, FAHA		
		Management of Hypertension in the Transplant Patient	Simin Goral, MD	•	
		Management of the Patient with an Adrenal Incidentaloma and Hypertension	Debbie Cohen, MD		
12:00pm – 2:00pm	231	Lunch Workshop: What Do You Know about Glomerular Disease?	Chairs: Patrick Nachman, MD, and Agnes Fogo, MD	• 101	2.0
		Case Presentations and Discussion	Agnes Fogo, MD Sanjeev Sethi, MD, PhD Michael Choi, MD, FNKF Patrick Nachman, MD		
12:00pm – 2:00pm	232	Lunch Workshop: Home Hemodialysis	Chairs: Joel Glickman, MD, and Fredric Finkelstein, MD, FNKF	• 101	2.0
		CKD Education with Emphasis on Home Therapies: What to Expect	Robert Quinn, MD		
		Outcomes in Home Hemodialysis	Fredric Finkelstein, MD, FNKF		
		Key Ingredients for a Successful Home Hemodialysis Program: Physician Perspective	Joel Glickman, MD		
		Key ingredients for a Successful Home Hemodialysis Program: Nursing Perspective	Lisa Koester, MSN, ANP, CNN-NP		

12:00pm – 2:00pm	233	Lunch Workshop: Comparative Effectiveness Research and Patient-Centered Outcomes Research: Generating Evidence for Kidney Care	Chair: Wolfgang Winkelmayer, MD, ScD, MPH, FASN	• 101	2.0
		What is Comparative Effectiveness Research and Why Do We Need it in Nephrology?	Wolfgang Winkelmayer, MD, ScD, MPH, FASN		
		A Primer on Methods in Comparative Effectiveness Research	Steven Brunelli, MD		
		Brave New World: Patient-Centeredness and Stakeholder Panels	Francesca Tentori, MD		
		Pragmatic Clinical Trials	Laura Dember, MD		
12:00pm – 2:00pm	234	Lunch Workshop: Commencement: Effective Transitions from Pediatric to Adult Care	Chairs: Susan Furth, MD, PhD, FNKF, and Bradley Warady, MD, FNKF		2.0
		Psychology of the Adolescent and Young Adult	Nataliya Zelikovsky, PhD		
		Adherence and the Adolescent	Ahna Pai, PhD		
		Transition Clinics	Bradley Warady, MD, FNKF		
2:00pm – 2:30pm		Break			
2:30pm – 3:30pm	265	NKF Presidential Address: Improving CKD Patient Health – We Have to Do Betterand We Can	Jeffrey Berns, MD, FNKF		1.0
		Shaul G. Massry Distinguished Lecture: The Anion Gap – An Enduring Concept: 1923 to 2015	Michael Emmett, MD, MACP		
3:30pm – 4:00pm		Break			
4:00pm – 5:30pm	266	Kidney Disease in Underserved Populations	Chairs: Rudolf Rodriguez, MD,		1.5
			FNKF, and Barry Straube, MD		
		The Epidemiology of Diabetes and Kidney Disease in the Latino Population: Lessons from Hispanic CRIC Study	Claudia Lora, MD, MS		
		Language Barriers: Providing Effective Care When Communication is a Challenge	Alicia Fernandez, MD		
		Challenges in Managing Latinos with CKD	Sylvia E. Rosas, MD, MSCE, FNKF		
4:00pm – 5:30pm	267	What's New with KDOQI®?	Chair: Michael Rocco, MD		1.5
		2014 KDOQI Hemodialysis Adequacy Update	Thomas Depner, MD		
		How to Write a Hemodiafiltration Prescription and How to Monitor Therapy	Raymond Vanholder, MD		
		The KDOQI Nutrition Update: A Unique Partnership with the American Academy of Nutrition and Dietetics	T. Alp Ikizler, MD		
		A Multidisciplinary KDOQI Vascular Access Update	Charmaine Lok, MD, MSc, FNKF		
6:00pm – 7:30pm		Opening Ceremonies and Networking Reception in the Exhibit Hall – Visit Posters/Exhibits		T	1.0*
7:30pm – 9:30pm	803	Dinner Symposium: Iron-Based Phosphate Binders: Clinical Implications of Novel Therapy Supported by an educational grant from Keryx Biopharmaceuticals, Inc.	Chair: Kevin Martin, MB, BCh, FACP	101	1.5
		Hyperphosphatemia and the Failing Kidney	Kevin Martin, MB, BCh, FACP		
		Phosphate Binders in Hemodialysis	Diana Jalal, MD		
		Benefits Beyond? Ferric Citrate and Anemia Management in	Kausik Umanath, MD		
		ESRD: Newest Evidence	ŕ		
			All Faculty		
7:30pm – 9:30pm	804	ESRD: Newest Evidence Case Study: Challenges in Management of		†©	1.5
7:30pm – 9:30pm	804	ESRD: Newest Evidence Case Study: Challenges in Management of Hyperphosphatemia Dinner Symposium: Utilizing Alternative Approaches to Achieve Uric Acid Target Levels Across a Multidisciplinary Team Supported by an educational grant from Takeda Physiologic Basis for Hyperuricemic Gout and the Kidney's	All Faculty	† • †	1.5
7:30pm – 9:30pm	804	ESRD: Newest Evidence Case Study: Challenges in Management of Hyperphosphatemia Dinner Symposium: Utilizing Alternative Approaches to Achieve Uric Acid Target Levels Across a Multidisciplinary Team Supported by an educational grant from Takeda	All Faculty Chair: Jay Wish, MD	†• †	1.5

Friday, March 27

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am	805	Breakfast Symposium: Nephropathic Cystinosis: New Insights and Approaches to Care Supported by an educational grant from Raptor Pharmaceuticals	Chair: Paul Goodyer, MD	†© }	1.5
		New Insights into Pathogenesis and Diagnosis	Minnie Sarwal, MD, MRCP, FRCP, DCH, PhD		
		New Approaches to Treatment and Monitoring	Paul Goodyer, MD	-	
		Transitioning to Adolescent and Adult Care	Sandra Amaral, MD, MHS	-	
6:00am – 7:45am	806	Breakfast Symposium: Evolving Management of Hyperphosphatemia in Chronic Kidney Disease Supported by an educational grant from Fresenius Medical Care Renal Therapies Group	Chair: Daniel Coyne, MD	101	1.5
		Clinical Obstacles to Controlling Hyperphosphatemia	Stuart Sprague, DO	_	
		Refinement of Dietary Phosphate Restriction	Orlando Gutierrez, MD, MMSc		
		Evolution of Phosphate Binders	Daniel Coyne, MD		
7:00am – 8:00am		Continental Breakfast in the Exhibit Hall – Visit Posters/Exhibits		(O)	1.0*
8:30am – 10:00am	268	What's New in Peritoneal Dialysis	Chairs: Joni Hansson, MD, FNKF, and Fredric Finkelstein, MD, FNKF	_	1.5
		PD Catheters: Who, Where, When, How and Outcomes	Robert Quinn, MD		
		Cycler Therapy: The Good, the Bad and What's New	Rajnish Mehrotra, MD, MBBS, FNKF	_	
		Timing of PD Initiation and Incremental PD	Joni Hansson, MD, FNKF		
8:30am – 10:00am	269	Hypertension, Lipids and Vitamin D: A Nephrocentric 2015 Update	Chair: Gavin Becker, MD, FRACP, FNKF		1.5
		Blood Pressure Management in CKD in the Era of JNC8	Raymond Townsend, MD, FAHA	_	
		Is HDL Good or Bad in CKD and ESRD Patients?	Hamid Moradi, MD	_	
		What's New in Vitamin D in CKD?	Joachim Ix, MD		
8:30am – 10:00am	290	Trainee Poster Tour	Chair: Sylvia E. Rosas, MD, MSCE, FNKF		
			Dan Negoianu, MD	-	
			Dena Rifkin, MD, MS, FNKF TBD	-	
10:00am – 10:30am		Break	100		
10:30am – 12:00pm	270	Wolves in Sheep's Clothing: Drugs and the Risk of	Chair: Wendy St. Peter, PharmD,		1.5
		Community Acquired AKI	FCCP, FASN, FNKF	-	
		Risk of Community Acquired AKI RAAS Blockade in CKD: A Delicate Balance	Roy Mathew, MD	-	
		Other Wolves in the Pack: Focus on Over-the-Counter NSAIDs Use	Stephen Seliger, MD Darren Grabe, PharmD	-	
10:30am – 12:00pm	271	Undocumented Immigrants: Care and Controversies	Chairs: Rudolph Rodriquez, MD, FACP, and Barry Straube, MD		1.5
		The Texas Experience: Emergent Dialysis for Undocumented Immigrants	Rajeev Raghavan, MD	-	
		Debate: RPA Recommendations vs. Safety Net Hospital Realities	Ruben Velez, MD Sharon Phillips, MBA, RN	-	
12:00pm – 2:00pm		Break in the Exhibit Hall (Lunch Served 12:15pm – 1:15pm) – Visit Posters/Exhibits		101	1.0*
2:00pm – 3:30pm	272	Acute Kidney Injury	Chair: Sean Bagshaw, MD, MSc, FRCPC		1.5
		Limitations of Creatinine and the Promise of Biomarkers in AKI	Anitha Vijayan, MD	-	
		Fluids are Drugs: Type, Dose, Toxicity, and AKI	Andrew Shaw, MD	-	
		Acute Kidney Injury Alerting: Clinical Information Sniffing	Manish Sood, MD	-	

	1.5
P.	
	1.5
Ͻ,	
Ο,	
Ĭ	1.0*
†●}	1.5
_	
_	
_	
_	
†⊚}	1.5
D,	
	D, T

Saturday, March 28

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
7:15am – 9:00am	809	Breakfast Symposium: Pathogenesis and Management of Nephrotic Syndrome in Primary Podocytopathies Supported in part by an educational grant from Mallinckrodt Pharmaceuticals	Chair: Fernando Fervenza, MD, PhD, FNKF	ΩÎ	1.5
		Insights Regarding the Pathogenesis and Evaluation of Nephrotic Syndrome	Laurence Beck, Jr., MD, PhD	_	
		Management of Nephrotic Syndrome: Treatment Strategies and Current Treatment Options	Brad Rovin, MD	_	
		A Case-Based Approach to Management of Nephrotic Syndrome	Fernando Fervenza, MD, PhD, FNKF		

As of February 26, 2015

8:00am – 11:30am		Break in the Exhibit Hall (Breakfast Served 8:00am – 9:00am) – Visit Posters/Exhibits		101	1.0*
9:30am – 11:00am	276	KEEP Healthy [™] : Insights into CKD Care	Chair: Kerri Cavanaugh, MD, FNKF, and Josef Coresh, MD, PhD, MHS		1.5
		Awareness and the Continued Need for CKD Detection	Beth Piraino, MD, FNKF		
		Evolution of the KEEP into KEEP Healthy	Peter McCullough, MD, FNKF		
		Insights into KEEP Healthy	Kerri Cavanaugh, MD, FNKF	'	
9:30am – 11:00am	277	Debate: Vaptans/Hyponatremia	Chairs: Lawrence Weisberg, MD, FNKF, and Richard Sterns, MD		1.5
		Overview of the Approach to Hyponatremia	Biff Palmer, MD		
		Management of Chronic Hyponatremia: Are Vaptans Now the First Line Treatment?	Mitch Rosner, MD	•	
		New Approaches to the Acute Management of Hyponatremia	Richard Sterns, MD	'	
9:30am – 11:00am	289	Late-Breaking Abstract Presentations	TBD		1.5
11:00am – 11:30am		Break			
11:30am – 1:00pm	235	Lunch Workshop: Evaluation and Management of Depression and Anxiety in CKD	Chair: Fredric Finkelstein, MD, FNKF	• 101	1.5
		Overview of Depression and Anxiety in CKD	Fredric Finkelstein, MD, FNKF		
		Diagnosis and Treatment of Depression in CKD	Susan Hedayati, MD		
		Diagnosis and Treatment for Anxiety in CKD	Rajnish Mehrotra, MD, MBBS, FNKF		
11:30am – 1:00pm	236	Lunch Workshop: Pregnancy Care in CKD	Chairs: Susan Furth, MD, PhD, FNKF, and Debbie Cohen, MD		1.5
		Preserving Fertility in Teens and Young Adults with Kidney Disease	Wendy Vitek, MD		
		Hypertension and Pregnancy (more than just preeclamsia)	Vesna Garovic, MD		
		Management of the Pregnant Patient with CKD/ESRD	Michelle Hladunwich, MD		
11:30am – 1:00pm	237	Lunch Workshop: Acid-Base and Electrolytes Supported by an educational grant from ZS Pharma	Chair: Lawrence Weisberg, MD, FNKF	• †© }	1.5
		Cases	Biff Palmer, MD		
		Cases	Lawrence Weisberg, MD, FNKF		
		Cases	Michael Emmett, MD, MACP		
11:30am – 1:00pm	238	Lunch Workshop: Challenges in PD	Chairs: Joel Glickman, MD, and Joni Hansson, MD, FNKF	• 101	1.5
		Diagnosis and Management of Ultrafiltration Failure	Joanne Bargman, MD, FRCPC		
		EPS: What Do You Discuss with Your Long-Term PD Patients?	Joni Hansson, MD, FNKF		
		PD Adequacy: What Formula - What V?	Joel Glickman, MD		
11:30am – 1:00pm	239	Lunch Workshop: The "Difficult Patient" on Hemodialysis	Chairs: Raymond Vanholder, MD, PhD	• 101	1.5
		Managing the "Difficult Dialysis Patient:" Ethical Foundations	Richard Goldman, MD		
		The Medical Director's Responsibilities Regarding "Difficult Dialysis Patients"	Jeff Perlmutter, MD		
		Nonadherence to the Dialysis Prescription: Truth and Consequences	Charlonda Thrower, LMSW		
11:30am – 1:00pm	240	Lunch Workshop: Onco-Nephrology: Myeloma, Primary Amyloidosis and other Monoclonal Deposition Diseases	Chair: Fernando Fervenza, MD, PhD, FNKF	• 101	1.5
		Overview of Paraproteinemic Kidney Diseases	Paul Sanders, MD	ı	
		Prognosis and Treatment for Myeloma and Amyloid	Laura Dember, MD	ı	
		Case Presentations	Agnes Fogo, MD	1	
1:00pm – 1:30pm		Break			

1:30pm – 3:00pm	278	Advance Care Planning in ESRD	Chair: Dena Rifkin, MD, MS, FNKF	1.5
		Physician Perspective	Michael Germain, MD	
		Social Work Perspective	Mary Beth Callahan, MSSW, ACSW, LCSW	
		Nursing Perspective	Glenda Harbert, RN, CNN, CPHQ	
		Dietitian Perspective	Maureen McCarthy, MPH, RD, CSR, LD	
1:30pm – 3:00pm	279	Biosimilars and Other "Similars" in Nephrology:	Chair: Amy Barton Pai, PharmD,	1.5
		Setting the Course for Uncharted Territories	BCPS, FASN, FCCP	
		Biosimilar ESAS: How Dissimilar are They?	Jay Wish, MD	
		Generic IV Iron Forumulations: Black Solutions in a	Amy Barton Pai, PharmD, BCPS,	
		Regulatory Gray Area	FASN, FCCP	
		Time for a New Direction? Pipeline Agents for Treating Anemia of CKD	Daniel Coyne, MD	
1:30pm – 3:00pm	280	The Dialysis Outcomes and Practice Pattern Study	Chairs: Amit Garg, MD, PhD,	1.5
		(DOPPS) Program: Expanding into New Clinical and Research Areas	FRCPC, FACP, and Adam Whaley- Connell, DO, MSPH, FNKF	
		CKDopps: Identifying Optimal Practices in Advanced Chronic Kidney Disease and the Dialysis Transition	Bruce Robinson, MD	
		PDOPPS: Extending the DOPPS Approach to Study Peritoneal Dialysis Practice Variation	Rajnish Mehrotra, MD, MBBS, FNKF	
		DOPPS Practice Monitor: Newest Trends in US dialysis Practice and Implications for Patients	Raymond Hakim, MD, PhD	
		EPOCH-RRT: Empowering Patients on Choice of Dialysis Modality	Francesca Tentori, MD	
3:00pm – 3:30pm		Break		
3:30pm – 5:00pm	281	Volume First: Is It About Time?	Chairs: Steven Brunelli, MD	1.5
		Consequences of Volume Overload in patients on Hemodialysis and Weight Gain/Time Conundrum	Steven Brunelli, MD	
		Deletionable of DD Control and Volume	Rajiv Agarwal, MD	
		Relationship of BP Control and Volume	Najiv Agai wai, ivib	
		Tools for Assessing Volume Status in Patients on Hemodialysis	Mitch Rosner, MD	
3:30pm – 5:00pm	282	Tools for Assessing Volume Status in Patients on		1.5
3:30pm – 5:00pm	282	Tools for Assessing Volume Status in Patients on Hemodialysis	Mitch Rosner, MD Chair: Wendy St. Peter, PharmD,	1.5
3:30pm – 5:00pm	282	Tools for Assessing Volume Status in Patients on Hemodialysis Managing Medications in CKD/ESRD Patients Medication Safety in ESRD: Pharmacoepidemiology	Mitch Rosner, MD Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF	1.5
3:30pm – 5:00pm	282	Tools for Assessing Volume Status in Patients on Hemodialysis Managing Medications in CKD/ESRD Patients Medication Safety in ESRD: Pharmacoepidemiology Perspective Starting a Medication Management Program in	Mitch Rosner, MD Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF Tara Chang, MD	1.5
3:30pm – 5:00pm 3:30pm – 5:00pm	282	Tools for Assessing Volume Status in Patients on Hemodialysis Managing Medications in CKD/ESRD Patients Medication Safety in ESRD: Pharmacoepidemiology Perspective Starting a Medication Management Program in Dialysis	Mitch Rosner, MD Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF Tara Chang, MD Maricela Lara-Nevarez, PharmD Katie Cardone, PharmD, BCACP,	1.5
		Tools for Assessing Volume Status in Patients on Hemodialysis Managing Medications in CKD/ESRD Patients Medication Safety in ESRD: Pharmacoepidemiology Perspective Starting a Medication Management Program in Dialysis Health Literacy and Patient Success	Mitch Rosner, MD Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF Tara Chang, MD Maricela Lara-Nevarez, PharmD Katie Cardone, PharmD, BCACP, FNKF Chair: Daniel Weiner, MD, MS,	
		Tools for Assessing Volume Status in Patients on Hemodialysis Managing Medications in CKD/ESRD Patients Medication Safety in ESRD: Pharmacoepidemiology Perspective Starting a Medication Management Program in Dialysis Health Literacy and Patient Success Literature Review	Mitch Rosner, MD Chair: Wendy St. Peter, PharmD, FCCP, FASN, FNKF Tara Chang, MD Maricela Lara-Nevarez, PharmD Katie Cardone, PharmD, BCACP, FNKF Chair: Daniel Weiner, MD, MS, FNKF	

Sunday, March 29

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
8:00am – 9:30am	284	BP Monitoring and Management	Chairs: Mahboob Rahman,		1.5
			MD, and Rajiv Agarwal, MD		
		What is the Role of ABPM and Home Blood Pressure	Mahboob Rahman, MD		
		Monitoring in CKD			
		When is the Best Time to Measure BP in a Dialysis Patient?	Rajiv Agarwal, MD		
		Medication Management of BP in Hemodialysis Patients: Is 3x a Week Dosing Appropriate?	Rajiv Agarwal, MD	_	

As of February 26, 2015

8:00am – 9:30am	285	Debate: Cinacalcet for CKD-MBD	Chairs: Gavin Becker, MD, FRACP, FNKF	1.5
		Overview of Secondary Hyperparathyroidism	Connie Rhee, MD	
		Pro: Cinacalcet is an Important Option for CKD-MBD Treatment	Stuart Sprague, DO, FNKF	
		Con: Cinacalcet is an Expensive Way to Make MBD Labs Look Good	Daniel Coyne, MD	
9:30am – 10:00am		Break		
10:00am – 11:30am	286	Renal Support in AKI	Chair: Joni Hansson, MD, FNKF	1.5
		What Would Outcome Be Without RRT in AKI?	Sean Bagshaw, MD, MSc, FRCPC	
		When Should we Optimally Start RRT in AKI?	Ronald Wald, MD	
		Should we Be Using More PD in AKI?	Fredric Finkelstein, MD, FNKF	
10:00am – 11:30am	287	What the Nephrologist Needs to Know About Under- recognized Endocrine Disorders in CKD	Chairs: David Salant, MD, and Daniel Weiner, MD, MS, FNKF	1.5
		The Thyroid-Kidney Interaction and its Impact on CKD Outcomes	Connie Rhee, MD	
		Testosterone Deficiency, Clinical Outcomes, and Management in CKD	Kirsten Johansen, MD	
		Fertility & Contraception	Muhammad Mustafa, MD	
11:30am		Meeting Adjourns		

[•] Separate Registration and/or Fee Required

 $\overline{\mathbb{T}}$ Cocktail Reception



st A maximum of 1.0 credit only will be awarded for Poster Sessions.